Home / Private raises / OrbiMed Asia Partners VI, L.P.
OrbiMed Asia Partners VI, L.P.
Private Equity Fund · New York, New York · $1.0B sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | D/A (update) | $1.0B | $1.0B | 72 | 506(b), 3(c), 3(c)(7) | Fund interests | Sep 30 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Sold through (placement agents)
| Broker-dealer | Solicited in |
|---|---|
| UBS Switzerland AG | — |
| MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED | All States |
| J.P. Morgan Securities LLC | All States |
No sales commission reported in the latest filing.
Issuer
| Industry | Pooled Investment Fund |
| Fund type | Private Equity Fund |
| Located | New York, New York |
| Entity | Limited Partnership |
| Incorporated | Cayman Islands, 2025 |
| Revenue range | Not Applicable |
| SEC CIK | 2087034 |
People named in the latest filing
| Name | Role |
|---|---|
| OrbiMed Asia GP VI, L.P. | General Partner of the Issuer (the "GPLP") |
| OrbiMed Advisors VI Limited | General Partner of the GPLP (the "GPLTD") |
| Carl L. Gordon | Director of the GPLTD |
| W. Carter Neild | Director of the GPLTD |
| Sunny Sharma | Director of the GPLTD |
| David G. Wang | Director of the GPLTD |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
